ナビゲーション
市場の見通し ストックスクリーナー 配当カレンダー イベントカレンダー 株式の格付け マーケットニュース
無料でお試しください

KalVista Pharmaceuticals

NASDAQ KALV
$12.49 0.49 4.08%
Today share price
米国
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Показатель: 16 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

419.46M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
364.31M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
2.01
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
34.72M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-1.39 %

Upcoming events KalVista Pharmaceuticals

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart KalVista Pharmaceuticals

Stock analysis KalVista Pharmaceuticals

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

もっと
-3.44 27.58
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

もっと
2.60 3.97
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

もっと
-2.96 10.54
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

もっと
0.45 0.24
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

もっと
-137.76 10.75

Price change KalVista Pharmaceuticals per year

12.83$ 43.08$
Min Max

Summary analysis KalVista Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure KalVista Pharmaceuticals

Revenue and net income KalVista Pharmaceuticals

All parameters

Stock news KalVista Pharmaceuticals

All news
15 2月 в 17:55

KalVista Pharmaceuticals Shares Rise 15% After Public Offering Prices

15 2月 в 17:55

KalVista Pharmaceuticals Shares Rise 15% After Public Offering Prices

7 7月 2023 в 19:30

KalVista Pharmaceuticals Shares Rise 12%, Company Expects to Submit FDA Application Next Year

7 7月 2023 в 19:25

KalVista Pharmaceuticals Shares Rise 12%, Company Expects to Submit FDA Application Next Year

5 1月 2023 в 14:50

KalVista Pharmaceuticals Names Benjamin Palleiko President >KALV

5 1月 2023 в 14:45

KalVista Pharmaceuticals Names Benjamin Palleiko President >KALV

31 10月 2022 в 14:10

KalVista Pharmaceuticals Sees Positive Data From Sebetralstat Study

31 10月 2022 в 14:10

KalVista Pharmaceuticals Sees Positive Data From Sebetralstat Study

31 10月 2022 в 14:10

KalVista Pharmaceuticals Sees Positive Data From Sebetralstat Study

31 10月 2022 в 14:10

KalVista Pharmaceuticals Sees Positive Data From Sebetralstat Study

5 10月 2022 в 20:06

KalVista Pharmaceuticals Shares Hit 52-Week Low for Second Day in a Row

5 10月 2022 в 20:01

KalVista Pharmaceuticals Shares Hit 52-Week Low for Second Day in a Row

4 10月 2022 в 13:50

KalVista Pharmaceuticals Ends Phase 2 Trial for KVD824

4 10月 2022 в 13:45

KalVista Pharmaceuticals Ends Phase 2 Trial for KVD824

8 6月 2022 в 15:31

KalVista Pharmaceuticals stock price target cut to $32 from $54 at Stifel Nicolaus

10 11月 2021 в 15:15

KalVista Pharmaceuticals Reports Productive Meeting With FDA

10 11月 2021 в 15:15

KalVista Pharmaceuticals Reports Productive Meeting With FDA

About company KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts.
Address:
55 Cambridge Parkway, Cambridge, MA, United States, 02142
Company name: KalVista Pharmaceuticals
Issuer ticker: KALV
ISIN: US4834971032
Country: 米国
Exchange: NASDAQ
Currency: $
IPO date: 2015-04-09
Sector: Healthcare
Industry: Biotechnology
Site: https://www.kalvista.com

On which stock exchange are KalVista Pharmaceuticals (KALV) stocks traded?

KalVista Pharmaceuticals (KALV) stocks are traded on NASDAQ.

What is the ticker of KalVista Pharmaceuticals stocks (KALV)?

The stock ticker of KalVista Pharmaceuticals’s stocks or in other words, the code is KALV. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does KalVista Pharmaceuticals (KALV) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, KalVista Pharmaceuticals (KALV) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are KalVista Pharmaceuticals (KALV) stocks traded?

KalVista Pharmaceuticals (KALV) stocks are traded on the NASDAQ exchange in dollars.

What is the price of KalVista Pharmaceuticals (KALV) stocks today?

The current price of KalVista Pharmaceuticals stocks on 15.05.2024 is 12.49 dollars. per share.

What is the dynamics of KalVista Pharmaceuticals (KALV) stocks from the beginning of the year?

KalVista Pharmaceuticals (KALV) quotes have increased by 2.8% from the beginning of the year up to 12.49 dollars. per 1 stocks.

How much did KalVista Pharmaceuticals (KALV) stocks increase in мае 2024?

This month KalVista Pharmaceuticals (KALV) quotes have increased by 2.55% to 12.49 dollars. per share.

How much are KalVista Pharmaceuticals (KALV) stocks worth?

Today, on October, 15.05.2024 KalVista Pharmaceuticals’s (KALV) stocks cost 12.49 dollars..

What is the market capitalization of KalVista Pharmaceuticals (KALV)?

Capitalization is the market value of KalVista Pharmaceuticals (KALV) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 15.05.2024, the market capitalization of KalVista Pharmaceuticals (KALV) is estimated at about 419458418 dollars.